Celldex Therapeutics (CLDX) Change in Accured Expenses (2016 - 2025)
Historic Change in Accured Expenses for Celldex Therapeutics (CLDX) over the last 16 years, with Q3 2025 value amounting to $13.1 million.
- Celldex Therapeutics' Change in Accured Expenses rose 85721.74% to $13.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.9 million, marking a year-over-year increase of 259792.35%. This contributed to the annual value of $11.6 million for FY2024, which is 2397.7% up from last year.
- Latest data reveals that Celldex Therapeutics reported Change in Accured Expenses of $13.1 million as of Q3 2025, which was up 85721.74% from $2.1 million recorded in Q2 2025.
- Over the past 5 years, Celldex Therapeutics' Change in Accured Expenses peaked at $16.4 million during Q4 2024, and registered a low of -$8.7 million during Q1 2025.
- Moreover, its 5-year median value for Change in Accured Expenses was -$139000.0 (2022), whereas its average is $1.4 million.
- Its Change in Accured Expenses has fluctuated over the past 5 years, first plummeted by 59133.86% in 2022, then skyrocketed by 288920.86% in 2023.
- Celldex Therapeutics' Change in Accured Expenses (Quarter) stood at -$550000.0 in 2021, then soared by 74.73% to -$139000.0 in 2022, then surged by 2889.21% to $3.9 million in 2023, then surged by 323.68% to $16.4 million in 2024, then dropped by 20.48% to $13.1 million in 2025.
- Its Change in Accured Expenses stands at $13.1 million for Q3 2025, versus $2.1 million for Q2 2025 and -$8.7 million for Q1 2025.